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FTR
 
 
 
F508 exhibits a correctable protein-folding
defect that leads to its misfolding and premature
degradation, which is the cause of cystic ﬁbrosis
(CF). Herein we report on the characterization of the
CFTR
 
 
 
F508 biogenic intermediate that is selected for
proteasomal degradation and identiﬁcation of cellular
components that polyubiquitinate CFTR
 
 
 
F508. Nonubiqui-
tinated CFTR
 
 
 
F508 accumulates in a kinetically trapped,
but folding competent conformation, that is maintained
in a soluble state by cytosolic Hsc70. Ubiquitination of
Hsc70-bound CFTR
 
 
 
F508 requires CHIP, a U box con-
C
 
taining cytosolic cochaperone. CHIP is demonstrated to
function as a scaffold that nucleates the formation of a multi-
subunit E3 ubiquitin ligase whose reconstituted activity
toward CFTR is dependent upon Hdj2, Hsc70, and the
E2 UbcH5a. Inactivation of the Hsc70–CHIP E3 leads
CFTR
 
 
 
F508 to accumulate in a nonaggregated state,
which upon lowering of cell growth temperatures, can
fold and reach the cell surface. Inhibition of CFTR
 
 
 
F508
ubiquitination can increase its cell surface expression and
may provide an approach to treat CF.
 
Introduction
 
CFTR is a Cl
 
 
 
 ion channel that is localized to the apical surface
of epithelial cells that line lung airways and glands (Riordan et
al., 1989). Cystic fibrosis (CF) is an autosomal recessive disease
and most CF patients inherit at least one CFTR
 
 
 
F508 mutant
allele. CFTR
 
 
 
F508 lacks F508 in nucleotide binding domain
(NBD) I and has a temperature-sensitive folding defect, which
causes its premature degradation by the ubiquitin proteasome
system (Denning et al., 1992; Jensen et al., 1995a; Ward et al.,
1995). Loss of CFTR function at the cell surface leads to
mortality in CF patients because of altered hydration of airway
epithelia and persistent lung infections (Welsh and Smith, 1993).
An interesting feature of CFTR
 
 
 
F508 is that when growth
conditions are altered, it can fold, escape the endoplasmic retic-
ulum quality control system (ERQC), and function at the cell
surface (Denning et al., 1992; Brown et al., 1996). Thus, the
development of agents that promote the folding or block the
degradation of nascent CFTR
 
 
 
F508 has the potential to provide
a therapeutic avenue for the treatment of CF. Rational design of
such therapeutics requires a basic understanding of the mechanism
for CFTR
 
 
 
F508 misfolding and the identification of the ERQC
machinery that selects CFTR
 
 
 
F508 for degradation.
CFTR is a 1,480 residue glycomembrane protein whose
proper function requires the formation of intramolecular con-
tacts between its two transmembrane domains, two cytoplasmic
NBDs, and a regulatory domain (R-domain; Xiong et al., 1997).
CFTR and CFTR
 
 
 
F508 biogenesis is inefficient with 60–75%
of CFTR and nearly 99% of CFTR
 
 
 
F508 being degraded before
reaching the cell surface (Ward and Kopito, 1994). Thus, the
kinetics of CFTR and CFTR
 
 
 
F508 folding are slow and non-
native biogenic intermediates of each appear to be actively
selected for degradation by ERQC systems. The nature of the
CFTR
 
 
 
F508 biogenic intermediate that is selected for degradation
is unknown, but CFTR and CFTR
 
 
 
F508 appear to assume
similar conformations at early stages of assembly (Zhang et
al., 1998). Because F508 is located on the surface of NBD1,
CFTR
 
 
 
F508 assembly is proposed to go off pathway at a late
stage (Lewis et al., 2004). The inability of CFTR
 
 
 
F508 to fold
properly makes it prone to aggregation (Qu and Thomas, 1996)
and causes some of its degradation intermediates to accumulate
in detergent-insoluble aggregates (Ward et al., 1995).
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The mechanism by which the cell monitors the conforma-
tional state of CFTR
 
 
 
F508 and makes protein triage decisions
that determine its fate are unclear. Current models suggest that
the folded state of CFTR and CFTR
 
 
 
F508 is surveyed by the
cytosolic chaperone Hsc70 and Hsp90 (Yang et al., 1993; Loo
et al., 1998; Zhang et al., 2001). The ER luminal lectin-binding
chaperone calnexin can form a complex with the immaturely
glycosylated B form of CFTR
 
 
 
F508, but a direct role for cal-
nexin in CFTR folding and/or degradation has not been demon-
strated (Pind et al., 1994; Okiyoneda et al., 2004).
Cytosolic Hsc70 functions in complexes with either folding
or degradatory cochaperones to mediate steps in CFTR folding
and degradation (Cyr et al., 2002). The type I Hsp40 cochaperone
Hdj-2 is farnesylated and localized to the cytoplasmic face of the
ER where it recruits Hsc70 to bind ribosome associated CFTR to
promote early stages of its assembly (Meacham et al., 1999).
Hsc70 can also interact with the degradatory cochaperone CHIP
to facilitate the proteasomal degradation of ER forms of CFTR
and CFTR
 
 
 
F508 (Meacham et al., 2001). Thus, cochaperones of
Hsc70 play a central role in determining the fate of nascent CFTR.
Mechanistic insight into how CHIP functions as a degrada-
tory cochaperone is now required to understand how the cell
makes protein triage decisions for CFTR
 
 
 
F508. CHIP contains
three NH
 
2
 
-terminal tetratricopeptide repeat motifs (TPR) that bind
the COOH terminus of Hsc70 (Scheufler et al., 2000) and a non-
canonical RING domain, termed the U box, which promotes inter-
actions with E2 enzymes (Ballinger et al., 1999). The TPR repeat
motifs and U box are essential for CHIP to mediate CFTR and
CFTR
 
 
 
F508 degradation (Meacham et al., 2001). Thus, CHIP
is proposed to interact with Hsc70 to form an E3 ubiquitin ligase
that targets CFTR
 
 
 
F508 for proteasomal degradation. However,
CHIP can function in a U box independent manner to alter the
Hsc70 polypeptide binding and release cycle and negatively influ-
ence the folding of some client proteins (Ballinger et al., 1999;
Dai et al., 2003). Thus, it is plausible that CHIP targets CFTR and
CFTR
 
 
 
F508 for degradation by acting as an antifolding factor.
Herein, we reconstituted CFTR ubiquitination with puri-
fied components and demonstrated that Hsc70 and CHIP func-
tionally interact with the E2 UbcH5a to form a multisubunit E3
ubiquitin ligase that polyubiquitinates the cytosolic subdo-
mains of CFTR. Inactivation of the Hsc70–CHIP E3 in cul-
tured cells drove the accumulation of a nonaggregated and
foldable CFTR
 
 
 
F508 degradation intermediate. These data
support a model for quality control in which aggregation of
CFTR
 
 
 
F508 is suppressed by Hsc70 and Hdj-2. However,
when CFTR
 
 
 
F508 folding intermediates become kinetically
trapped in a nonnative state, CHIP attracts UbcH5a to Hsc70–
CFTR
 
 
 
F508 complexes and thereby facilitates CFTR
 
 
 
F508
ubiquitination and degradation.
 
Results
 
Purified CHIP functions as an Hdj-2–, 
Hsc70-, and UbcH5a-dependent E3 
ubiquitin ligase to polyubiquitinate CFTR
 
To investigate whether CHIP targets CFTR for degradation by
acting as a U box–dependent E3 ubiquitin ligase we sought to
reconstitute CFTR ubiquitination. To accomplish this goal
CHIP, Hsc70, Hdj-2, and the E2 UbcH5a were overexpressed
and purified from 
 
Escherichia coli
 
. UbcH5a was chosen as the
E2 for these experiments because it cooperates with CHIP to
promote polyubiquitin chain assembly (Jiang et al., 2001). The
CFTR substrate used for this ubiquitination reaction was gst–
NBD1–R (Naren et al., 1999), which contains binding sites for
Hdj-2 and Hsc70 (Meacham et al., 1999).
Gst–NBD1–R was incubated with different combina-
tions of chaperones and ubiquitination enzymes and its ubiq-
uitination was monitored by analyzing the retardation of
its mobility on SDS-PAGE gels (Fig. 1 A). E1 and UbcH5a
were unable to facilitate the ubiquitination of gst–NBD1–R
and the addition of CHIP lead to the formation of a small
quantity of ubiquitinated gst–NBD1–R. The presence of
Hsc70 or Hdj-2 in combination with CHIP further stimulated
the ubiquitination by UbcH5a, but the efficiency of this reac-
tion remained low with 
 
 
 
3% of gst–NBD1–R being detected
as a mono-, di-, or triubiquitinated species. However, 
 
 
 
85%
of gst–NBD1–R was polyubiquitinated when E1, UbcH5a,
Hsc70, Hdj-2, and CHIP were jointly present. Mutation of
conserved residues in CHIPs U box, H260A and P269A,
greatly reduced gst–NBD1–R polyubiquitination. In addi-
tion, mutation of K30A in the TPR repeat domain reduced
CHIPs ubiquitination activity to levels observed when CHIP
and Hdj-2 were present, but Hsc70 was omitted (Fig. 1, A
and C). CHIP cooperates with UbcH5a, Hsc70, and Hdj-2 in
a TPR repeat and U box–dependent manner to facilitate
CFTR polyubiquitination.
U box proteins function as E3 enzymes to stimulate E2
dependent polyubiquitin chain assembly and in some cases act
as E4 enzymes to elongate ubiquitin chains on monoubiqui-
tinated proteins (Koegl et al., 1999; Cyr et al., 2002). The data
presented indicates that CHIP acts in concert with Hsc70 and
Hdj-2 as an E3 to stimulate UbcH5a ubiquitination activity.
This conclusion is supported by the observation that UbcH5a
does not monoubiquitinate, and CHIP cooperates with Hsc70
and Hdj-2 to stimulate the rate at which UbcH5a converts gst–
NBD1–R into a polyubiquitinated species (Fig. S1).
To evaluate the specificity of CHIPs ubiquitination activ-
ity, its ability to cooperate with the mammalian E2s Ubc6 and
Ubc7 (Tiwari and Weissman, 2000; Lenk et al., 2002) to facili-
tate gst–NBD1–R ubiquitination was examined (Fig. 1 B).
Ubc6 and Ubc7 were used because these E2s mediate the ubiq-
uitination of ERAD substrates in cultured cells and their puri-
fied forms function in vitro to facilitate polyubiquitin chain as-
sembly (Tiwari and Weissman, 2001). In reaction cocktails that
contained E1, UbcH5a, Hsc70, Hdj2, and CHIP, gst–NBD1–R
was converted to a polyubiquitinated species in time-dependent
fashion (Fig. 1 B). However, after 180 min of incubation a
polyubiquitinated form of gst–NBD1–R was not detected when
the purified E2 domain of Ubc6 or Ubc7 was substituted for
UbcH5a in otherwise identical reaction cocktails. Thus, CHIP
appears to specifically recognize UbcH5a.
Next, the ability of UbcH5a C85A to facilitate the poly-
ubiquitination of gst–NBD1–R was determined (Fig. 1 D).
UbcH5a C85A is a form of UbcH5a in which its active site 
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cysteine that accepts a charged ubiquitin from E1 has been
mutated. UbcH5a C85A is predicted to interact with the U
box on CHIP, but should not facilitate polyubiquitin chain as-
sembly because it cannot be conjugated to ubiquitin. This
supposition was found to be true as UbcH5a C85A was un-
able to cooperate with CHIP to promote the polyubiquitina-
tion of gst–NBD1–R. Hence, the Hsc70- and Hdj-2–depen-
dent reconstitution of CFTR polyubiquitination requires the
action of the CHIP TPR and U box domains and the active
site cysteine of UbcH5a.
 
Overexpression of UbcH5a C85A in 
cultured cells inhibits CFTR and 
CFTR
 
 
 
F508 degradation
 
To access whether or not UbcH5a is an in vivo component of
Hsc70–CHIP E3, the effect that UbcH5a and UbcH5a C85A
overexpression in HEK293 cells had on CFTR biogenesis was
determined (Fig. 2 A). In addition, we compared the effect of
UbcH5a or UbcH5a C85A overexpression on CFTR biogenesis
to that of wild-type and dominant negative mutant forms of the
human E2s Ubc6 and Ubc7 (Fig. 2 A). Elevation of UbcH5a
levels caused a decrease in the accumulation of the immaturely
glycosylated ER localized B form and the maturely glycosyl-
ated plasma membrane localized C form of CFTR. In contrast,
overexpression of UbcH5a C85A led to a severalfold increase
in the steady-state level of the B and C form of CFTR. Ubc6
and Ubc6 C91S overexpression were also observed to influ-
ence CFTR expression levels, but the effect that Ubc6 C91S
had on the accumulation of the B form of CFTR was modest
when compared with results obtained with UbcH5a C85A. On
the other hand, Ubc7 and Ubc7 C89S overexpression did not
cause a detectable change in the steady-state level of CFTR and
CFTR
 
 
 
F508. Because Ubc6 does not appear to interact with
CHIP (Fig. 1), the effect that its overexpression has on CFTR
biogenesis appears to result from its ability to function with ad-
ditional quality control factors that monitor the folded state of
CFTR (Gnann et al., 2004).
To explore the reason why overexpression of UbcH5a
C85A drove the B form of CFTR to accumulate, its effect on
the kinetics of CFTR and CFTR
 
 
 
F508 degradation was deter-
mined (Fig. 2, B and C). In pulse-chase experiments, UbcH5a
C85A overexpression increased the quantity of the B form of
CFTR and CFTR
 
 
 
F508 present at the beginning of the chase
period 
 
 
 
1.5–3-fold (Fig. 2, legend). The UbcH5a C85A in-
duced increase in CFTR and CFTR
 
 
 
F508 levels appeared to
result from the impaired degradation of nascent CFTR and
CFTR
 
 
 
508 because the half-life of the B form of each was in-
creased two to threefold (Fig. 2, D and E). In addition, the mat-
uration efficiency of CFTR in the presence or absence of
UbcH5a C85A was around 25% (Fig. 2 D). Thus, inhibition of
the Hsc70–CHIP E3 complex via UbcH5a C85A overexpres-
sion inhibits CFTR degradation, but does not interfere with
CFTR folding efficiency.
To gain additional support for the interpretation that CHIP
and UbcH5a interact with each other to select nascent CFTR
and CFTR
 
 
 
F508 for degradation we demonstrated that the co-
expression of CHIP and UbcH5a enhanced the effect that indi-
vidual forms of each had on CFTR
 
 
 
F508 degradation (Fig. 2 D).
When CHIP or UbcH5a was overexpressed alone, steady-state
levels of CFTR
 
 
 
F508 were reduced to 30 and 41% of control
levels
 
,
 
 respectively. Yet, when CHIP and UbcH5a were coex-
pressed, CFTR
 
 
 
F508 accumulation was reduced by 
 
 
 
98%.
 
Overexpression of Ubch5a C85A does 
not generally inhibit ERAD
 
To ascertain whether or not UbcH5a C85A overexpression
generally inhibited ERAD or specifically blocked CFTR degra-
dation, its effect on the degradation of the T cell receptor 
 
 
Figure 1. Reconstitution of CFTR ubiquitination. (A) Ubiquitination of
gst–NBD1–R. (B) Ubc6 and Ubc7 cannot cooperate with Hsc70 and
CHIP to ubiquitinate gst–NBD1–R. (C) CHIP K30A is defective in poly-
ubiquitination. (D) UbcH5a C85A cannot ubiquitinate Gst–NBD–R. Ubiqui-
tination of Gst–NBD–R (1  M) was performed at 37 C and where indicated
the following components were present: UbcH5a (4  M), UbcH5a C85A
(4  M), Ubc6 (4  M), Ubc7 (4  M), CHIP (3  M), CHIP K30A (3  M),
Hsc70 (2  M), and Hdj2 (4  M). In 1B-D Hsc70 and Hdj-2 were in all
reactions except for lane 1. Incubations in A, C, and D were for 2 h.
Ubiquitination of Gst–NBD–R was determined by Western blot with  -R
domain antibody. In the x-ray films shown in A–D the band that corre-
sponds to Gst–NBD–R is overexposed to allow for the visualization of its
ubiquitinated forms. Quantitation of shorter exposures of these x-ray films
indicates that  85% of Gst–NBD–R is polyubiquitinated by the joint action
of UbcH5a, Hsc70, Hdj-2, and CHIP (A, lane 5). When Hsc70 or Hdj-2
were absent (A, lanes 2 and 3), UbcH5a and CHIP ubiquitinated  3%
of Gst–NBD–R. 
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subunit (TCR
 
 
 
) was examined (Fig. 3 A). TCR
 
 
 
 is a trans-
membrane protein that exposes a large extracellular domain in
the ER lumen whose unassembled form is degraded via an
ERAD pathway that uses the E2s Ubc6 and Ubc7 (Tiwari and
Weissman, 2001; Lenk et al., 2002). Pulse chase analysis re-
vealed that TCR
 
 
 
 had a half-life of around 1 h in absence or
presence of UbcH5a C85A (Fig. 3, A and C). In addition, the
overexpression of CHIP was not observed to influence the rate
of TCR
 
 
 
 turnover (unpublished data). In contrast, overexpres-
sion of either Ubc6 C91S or Ubc7 C89S led to an increase in
the half-life of TCR
 
 
 
 from 1 h to 1.5 and 2 h, respectively.
Thus, UbcH5a C85A overexpression does not detectably hinder
the turnover of a transmembrane ERAD substrate whose degra-
dation can be blocked by interference with the action of Ubc6
and Ubc7.
Because the membrane topology of TCR
 
 
 
 differs from
that of CFTR, we also examined the sensitivity of apolipopro-
tein B48 (ApoB48) degradation to overexpression of UbcH5a
C85A. ApoB48 is a 2,15–amino acid residue secretory protein
whose nascent form has features that are similar to CFTR be-
cause it exposes surfaces in the ER lumen and cytosol, and is a
substrate of cytosolic Hsp70 and Hsp90 (Gusarova et al.,
2001). ApoB48 folding and exit from the ER requires its as-
sembly into complexes with lipids, and unassembled forms are
degraded via a pathway that involves the transmembrane E3
Gp78, which can interact with Ubc7 (Cyr et al., 2002; Liang et
al., 2003). The overexpression of CHIP does not accelerate
Apob48 degradation (Meacham et al., 2001). Likewise, the
overexpression of UbcH5a C85A does not have a detectable ef-
fect on the rate of ApoB48 degradation (Fig. 3, B and C). Thus,
the overexpression of UbcH5 C85A does not generally inhibit
the function the cellular quality control machinery.
 
A detergent-soluble CFTR
 
 
 
F508 
degradation intermediate accumulates 
upon inactivation of the Hsc70–CHIP E3 
complex
 
CFTR and CFTR
 
 
 
F508 biogenic intermediates appear to be
aggregation prone and therefore are selected for ubiquitination
and proteasomal degradation. When the proteasome is inhib-
ited, polyubiquitinated CFTR
 
 
 
F508 accumulates in detergent-
insoluble aggregates (Ward et al., 1995), but nonubiquitinated
CFTR
 
 
 
F508 biogenic intermediates are not well character-
ized. To investigate the aggregation state of nonubiquitinated
CFTR
 
 
 
F508, we modulated the activity of the Hsc70–CHIP
E3 and determined the detergent solubility of the CFTR and
CFTR
 
 
 
F508 biogenic intermediates that accumulated (Fig. 4).
Overexpression of UbcH5a and CHIP caused an overall de-
crease in the pool of CFTR and CFTR
 
 
 
F508 and none of the B
form was detected in the Triton X-100–insoluble fraction.
When UbcH5a C85A was overexpressed, severalfold more of
 
Figure 2.
 
Degradation of CFTR and CFTR
 
 
 
F508 is inhibited by over-
expression of UbcH5A C85A.
 
 (A) Western blot analysis of CFTR levels
upon overexpression of the E2s UbcH5A, Ubc6, and Ubc7. HEK293 cells
were transfected transiently with expression plasmids that encode the
indicated proteins. Total cell extracts were prepared 24 h after transfec-
tion in SDS-PAGE sample buffer. Nitrocellulose was probed with 
 
 
 
-CFTR and
developed. The immaturely glycosylated ER localized B form and maturely
glycosylated plasma membrane associated C form of CFTR are denoted
as B and C, respectively. (B and C) UbcH5A C85A overexpression slows
the rate of CFTR and CFTR
 
 
 
F508 degradation. Cells were labeled for 20
min with 
 
35
 
S-translabel and a chase period was initiated by the addition of
cycloheximide. At the indicated times, 
 
35
 
S-CFTR or 
 
35
 
S-CFTR
 
 
 
F508 was
immunoprecipitated from cell extracts. CFTR or CFTR
 
 
 
F508 isolated in
this manner was detected by SDS-PAGE and fluorography. (D and E)
Graphs illustrate the processing efficiency and half-life of CFTR and
CFTR
 
 
 
F508. Relative CFTR and CFTR
 
 
 
F508 levels were quantitated by
laser densitometry of the x-ray films shown in B and C, respectively. Values
were normalized to the quantity of the B form of CFTR and CFTR
 
 
 
F508
present at 
 
t 
 
  
 
0 under the indicated experimental condition levels. 
 
t   0
values for the B form of CFTR were 1.1 and 1.8 OD, in the absence and
presence of UbcH5a C85A, respectively. t   0 values for the B form of
CFTR F508 were 2.3 and 7.0 OD, in the absence and presence of
UbcH5a C85A, respectively. (F) CHIP and UbcH5a jointly reduce levels
of CFTR F508 in Western blots.CFTR BIOGENESIS • YOUNGER ET AL. 1079
the B and C form of CFTR accumulated in the Triton X-100–
soluble fraction. To our surprise, we also observed UbcH5a
C85A overexpression to drive a severalfold increase in the
quantity of the B form of CFTR F508 that accumulated in a
Triton X-100–soluble state. Under these experimental condi-
tions, we also observed a small quantity of the C form of CFTR
in the detergent-insoluble fraction. Because the C form of
CFTR is typically soluble in Triton X-100, this material ap-
pears to represent a minor contamination of the detergent-
insoluble fraction with detergent soluble material.
Paradoxically, we observed markedly different results
when the action of the Hsc70–CHIP E3 was blocked via over-
expression of CHIP P269A. CHIP P269A inhibited degrada-
tion of the B form of CFTR and CFTR F508, but the degrada-
tion intermediate that accumulated was insoluble in Triton
X-100 (Fig. 4, A and B). In addition, CHIP P269A blocked
the glycolytic maturation of CFTR from the B to C form.
The effect that CHIP and CHIP P269A had on CFTR and
CFTR F508 biogenesis was resultant from interactions with
Hsc70 because the TPR mutant CHIP K30A had no effect on
CFTR biogenesis (Fig. 4).
How do we explain the observation that the overexpres-
sion of UbcH5a C85A and CHIP P269A block CFTR degra-
dation, but yet cause the degradation intermediates that ac-
cumulate to exhibit differential detergent solubility? CHIP
P269A blocks the glycolytic maturation of CFTR, and thus
retains the ability of CHIP to interact with Hsc70 to arrest
CFTR folding (Meacham et al., 2001). Therefore, because
CHIP P269A can hinder Hsc70s protein folding function, but
can’t promote CFTR degradation, it causes nonnative CFTR
to aggregate. In HEK293 cells CHIP levels are normally 10-
fold lower than those for Hsc70 (Meacham et al., 2001).
Hence, when UbcH5a C85A is overexpressed the levels of
CHIP–UbcH5a C85A complexes that form should not be
more than one-tenth the level of Hsc70. Ergo, the overexpres-
sion of UbcH5a C85A can block CFTR degradation, but
the levels of CHIP–UbcH5a C85A complexes are not high
enough to interfere with Hsc70s ability to suppress CFTR ag-
gregation. Therefore, UbcH5a C85A drives the accumulation
of a CFTR F508 degradation intermediate that is stabilized
in a nonaggregated state.
If the aforementioned interpretations are correct and
UbcH5a C85A specifically inactivates the U box of CHIP to
block CFTR degradation, then the coexpression of UbcH5a
C85A and CHIP, should have the same effect on CFTR biogen-
esis as CHIP P269A. Indeed, we observed that the simulta-
neous overexpression of CHIP and UbcH5a C85A blocked the
glycolytic maturation and degradation of CFTR and drove the
B form of CFTR to accumulate as a detergent-insoluble aggre-
gate (Fig. 4 D, lane 1 vs 5).
The data presented in Fig. 4 are important for the follow-
ing reasons. First, these data indicate that interference with
Hsc70–CHIP E3 activity drives the accumulation of a novel
nonaggregated CFTR F508 biogenic intermediate. Second,
these data demonstrate that proper chaperone function of Hsc70
is critically important for maintenance of nonnative CFTR and
CFTR F508 in a detergent soluble state. Third, the observation
that UbcH5a C85A and CHIP coexpression makes CHIP be-
have like CHIP P269A supports the interpretation that CHIP
and UbcH5a functionally interact in vivo to ubiquitinate CFTR.
Characterization of the nonaggregated 
CFTR F508 degradation intermediate
To investigate the nature of the detergent-soluble CFTR F508
degradation intermediate that accumulated when UbcH5a
Figure 3. Insensitivity of TCR  and ApoB48 turnover to inhibition of the
Hsc70–CHIP E3. (A) TCR  degradation. (B) ApoB48 turnover. HEK293
cells were transiently transfected with expression plasmids for the indi-
cated proteins. 24 h after transfection, cells were labeled for 20 min with
35S-translabel. A chase period was initiated by the addition of cycloheximide
and, at the indicated times, cells were harvested and lysed. TCR  or
ApoB48 were immunoprecipitated from cell extracts and detected by SDS-
PAGE and autoradiography. (C) Quantitation of TCR  and Apob48 levels,
the relative amount of each protein present at t   0 is expressed as
100% of control.JCB • VOLUME 167 • NUMBER 6 • 2004 1080
C85A was overexpressed, we compared its ubiquitination state
to that of degradation intermediates that accumulate in re-
sponse to proteasome inhibition by ALLN, or overexpression
of a dominant negative form of p97 (p97 QQ; Ye et al., 2003).
P97 is a cytosolic chaperone that extracts polyubiquitinated
proteins from the ER and participates in CFTR F508 degrada-
tion (Ye et al., 2003; Dalal et al., 2004). Nonubiquitinated
CFTR F508 migrates on SDS-PAGE gels with the same mo-
bility as its B form, where as polyubiquitinated CFTR F508,
which accumulated when its degradation was blocked by
ALLN or p97 QQ, migrates on SDS-PAGE gels as a high mo-
lecular weight smear (Fig. 5 A). CFTR F508 that accumulated
in response to UbcH5a C85A overexpression did not migrate
as a high molecular smear and, therefore, represents a non-
ubiquitinated species. This result is consistent with the notion
that UbcH5a C85A inhibits CFTR F508 ubiquitination and
thereby blocks its degradation.
Next, we examined the effect that modulating Hsc70–
CHIP E3 action had on complex formation between Hsc70 and
CFTR F508 degradation intermediates (Fig. 5 B). This was
accomplished by coimmunoprecipitating Hsc70–CFTR F508
complexes with  -Hsc70 antibody from radiolabeled cells that
were transfected with the indicated form of UbcH5a or CHIP.
Overexpression of UbcH5a or CHIP reduced the levels of im-
munoprecipitable CFTR F508, whereas UbcH5a C85A over-
expression caused CFTR F508 to accumulate several fold. On
Figure 4. Triton X-100–soluble CFTR and CFTR F508 degradation inter-
mediates accumulate in response to overexpression of UbcH5a C85A.
(A and B) Analysis of the solubility of CFTR or CFTR F508. HEK293 were
transiently tranfected with vectors that express the indicated proteins. As
indicated, the proteasome inhibitor ALLN (200  M) was added to the
growth medium 4 h preceding cell lysis. (C) Coexpression of CHIP and
UbcH5a C85A blocks CFTR folding and causes its biogenic intermediates
to aggregate. CFTR and CFTR F508 were detected by Western blot. The
fractionation of cell extracts into Triton X-100–soluble and –insoluble material
was performed as described in the Materials and methods. The upper
panel represents Triton X-100–soluble material, where as the lower part
represents Triton X-100–insoluble material. The immaturely glycosylated
B form of CFTR and CFTR F508, and maturely glycosylated C form of
CFTR are denoted.
Figure 5. Characterization of the CFTR F508 biogenic intermediate that
accumulates when UbcH5a C85A is overexpressed. (A) Analysis of
CFTR 508 levels when its proteasomal degradation is inhibited by different
methods. HEK293 cells were transfected with the indicated expression
vectors and harvested in SDS sample buffer 24 h later. ALLN (200  M)
was added to culture media 4 h before cell harvest. CFTR F508 levels
were determined by Western blot. Ubiquitinated CFTR F508 runs as a
high molecular smear on SDS-PAGE gels and is denoted. (B) Complex
formation between Hsc70 and CFTR F508. Cells were transfected with
the indicated expression plasmids and 24 h after incubation they were
radiolabeled for 30 min with 
35S-translabel and harvested. Half of each
cell pellet was lysed under denaturing or native buffer conditions and im-
munoprecipitations were performed and analyzed by fluorography. (C)
CFTR F508 that accumulates in the presence of UbcH5a C85A is glyco-
sylated. Cells were harvested and half of each respective lysate was
treated with endoglycosidase H whereas the other half served as the control.
A and B denote the mobility of nonglycosylated and immaturely glycosylated
forms of CFTR F508, respectively.CFTR BIOGENESIS • YOUNGER ET AL. 1081
the other hand, CHIP P269A, which inhibits CFTR degradation
and caused CFTR F508 to aggregate (Fig. 4), reduced the total
amount of CFTR 508 that could be immunoprecipitated from
cell extracts. The newly synthesized pool of Hsc70 detected by
immunoprecipitation was not significantly changed when the
levels of the components of the Hsc70–CHIP–UbcH5a E3
complex were altered. Yet, we did observe that the levels of
Hsc70–CFTR F508 complexes were lower when UbcH5a and
CHIP were overexpressed, and were elevated when UbcH5a
C85A was overexpressed. Nonetheless, under all of the afore-
mentioned experimental conditions tested, the changes in the
levels of Hsc70–CFTR F508 complexes appeared propor-
tional to changes in the total amount of immunoprecipitable
CFTR F508 present in the cell extracts. The major conclu-
sion  drawn from these results is that the detergent soluble
CFTR F508 degradation intermediate that accumulates upon
UbcH5a C85A overexpression is associated with Hsc70.
Data presented thus far suggest that inhibition of Hsc70–
CHIP E3 activity drives the accumulation of an ER membrane
inserted CFTR F508 biogenic intermediate that is arrested at a
biogenic stage where it has the potential to either fold or be de-
graded. If this is the case then the CFTR F508 that accumu-
lates in response to UbcH5a C85A overexpression should be
glycosylated. Indeed, we observed that the gel mobility of the
CFTR F508 that accumulates in response to UbcH5a C85A
overexpression was increased when total cell extracts were
treated with endoglycosidase H, which removes ASN-linked
glycans from glycoproteins (Fig. 5 C). Thus, inhibition of
the Hsc70–CHIP E3 activity promotes the accumulation of an
immaturely glycosylated and detergent soluble form of CFTR F508
that is bound to Hsc70.
CFTR F508 that accumulates in the ER 
when Hsc70–CHIP action is blocked can 
fold to the native state
To ascertain whether or not the CFTR F508 biogenic interme-
diate that accumulates in response to inhibition of Hsc70–
CHIP E3 function is capable of folding we determined if it
could be chased to its maturely glycosylated C form (Fig. 6 A).
Transiently transfected HEK293 cells were grown for 24 h af-
ter transfection and then treated with cycloheximide to inhibit
new protein synthesis. The fate of the accumulated CFTR F508
was then monitored by Western blot after the indicated chase
incubation at 37  or 26 C (Fig. 6 A). The low-temperature chase
incubation was incorporated into the design of this experiment
because nascent CFTR F508 exhibits a temperature-sensitive
folding defect and can fold to the native state and accumulate
in its maturely glycosylated C form when cells are cultured at
26 C (Denning et al., 1992).
When control cells were allowed to synthesize
CFTR F508 at 37 C and were then incubated at either 37  or
26 C,  90% of the total protein present at t   0 was degraded
during the 8-h chase period. When UbcH5a C85A was coex-
pressed with CFTR F508 and a chase incubation was per-
formed at 37 C, 40 to 50% of the total CFTR F508 present at
t   0 remained in the cell for up to 24 h. However, even though
UbcH5a C85A stabilized the B form of CFTR F508, its con-
version to the C form was not detected during the chase reac-
tion at 37 C. In contrast, when chase incubations were per-
formed at 26 C, a significant portion of the CFTR F508 that
was stabilized in the B form by UbcH5a C85A, was converted
to the maturely glycosylated C form. The formation of the ma-
turely glycosylated C form of CFTR F508 was proportional to
the loss of B form and could be detected in cells after 8 h of
chase time and appeared to be complete after 16 h. The glyco-
lytic maturation of CFTR F508 observed in the presence of
UbcH5a C85A during the chase incubation at 26 C was inhib-
Figure 6. Glycolytic maturation of CFTR F508 degradation intermediates
that accumulate in response to UbcH5a C85A overexpression. (A) The
CFTR F508 that accumulates when UbcH5a C85A is overexpressed
becomes maturely glycosylated when cell growth temperatures are reduced
to 26 C. HEK293 cells were transiently transfected with the indicated plas-
mids and were treated with cycloheximide (25  g/ml) 24 h later. Cells
were then either shifted to 26 C or maintained at 37 C for the indicated
time.(B) Glycolytic processing of CFTR F508 in cells incubated at 26 C
for 16 h is blocked by BFA and enhanced by the chemical chaperone
TMAO (75 mM). (C) COS-7 cells are capable of maintaining CFTR F508
degradation intermediates in a folding competent state. This experiment
was performed as described for panel A except that the chase time was
for 24 h at 26 C. The immaturely glycosylated and maturely glycosylated
forms of CFTR F508 are denoted as B and C, respectively.JCB • VOLUME 167 • NUMBER 6 • 2004 1082
ited by brefeldin A (BFA) and appears to result from traffick-
ing of CFTR F508 out of the ER (Fig. 6 B). To determine
if we could further increase the folding efficiency of the
CFTR F508 that accumulated in the presence of UbcH5a
C85A, cells were treated with the chemical chaperone TMAO
just before the initiation of the chase reaction (Brown et al.,
1996). TMAO treatment of cells increased the quantity of
UbcH5a C85A stabilized CFTR F508 that could be processed
to a maturely glycosylated C form around twofold. Thus, a por-
tion of CFTR F508 that accumulated in response to inhibition
of its ubiquitination remains in a foldable state that can be
brought back on pathway by alteration of cell growth tempera-
tures or chemical chaperones.
To probe whether inhibition of the Hsc70–CHIP complex
stabilizes CFTR F508 in a folding competent conformation in
more than one cell type, we examined the effect that UbcH5a
C85A overexpression had on CFTR F508 expression and
folding in COS7 cells (Fig. 6 C). UbcH5a C85A overexpres-
sion was again observed to drive the accumulation of the B
form of CFTR F508. In addition, a significant portion of the B
form that accumulated in the presence of Ubc5Ha C85A could
be chased at 26 C, in a BFA-sensitive manner, to the maturely
glycosylated C form. Hence, the Hsc70–CHIP complex can
regulate biogenesis of CFTR F508 in more than one cell type.
To demonstrate that the CFTR F508 that was converted
to the C form during the 26 C chase incubation was trafficked
to the cell surface the localization of GFP–CFTR F508 was
examined under these experimental conditions and compared
with that of GFP–CFTR (Fig. 7). At 37 C, GFP–CFTR was de-
tected both at the cell surface and in a perinuclear location that
corresponds to the ER (Moyer et al., 1998). At 37 C, in the
presence or absence of UbcH5a C85A, GFP–CFTR F508 was
only detected in its soluble ER form. However, when UbcH5a
C85A-transfected cells were cultured for 24 h at 37 C, treated
with cycloheximide, and then incubated at 26 C for 4 h, a pool
of GFP–CFTR F508 accumulated, in a BFA-sensitive fashion,
at the cell surface.
The collective data presented in Figs. 5–7 demonstrate that
when the activity of the Hsc70–CHIP ubiquitin ligase is re-
duced, CFTR F508 accumulates as an immaturely glycosylated
species that is not a dead-end folding intermediate. Instead, the
cell can maintain a pool of kinetically trapped CFTR F508
folding intermediates in a detergent soluble and foldable state.
Discussion
Herein we provide new insights into how CFTR and
CFTR F508 biogenic intermediates are partitioned between
folding and degradation pathways. The data presented suggest
a model for quality control in which newly synthesized CFTR
and CFTR F508 initiate folding, but intermediates of each
accumulate in a kinetically trapped conformation that is
maintained in a soluble state by Hsc70. CHIP then interacts
with Hsc70 and functions via a two-step mechanism to at-
tract UbcH5a into Hsc70–CFTR complexes. Then the Hsc70–
CHIP–UbcH5a E3 formed acts to polyubiquitinate CFTR.
Interestingly, inhibition of Hsc70–CHIP E3 activity
caused the accumulation of a nonaggregated and ER localized
CFTR F508 biogenic intermediate that was bound by Hsc70.
Addition of chemical chaperones to growth media and reduc-
tion of cell growth temperatures permitted this nonubiquiti-
nated CFTR F508 degradation intermediate to fold, exit the
ER, and accumulate on the cell surface. These are the first data
that describe a nonubiquitinated CFTR F508 biogenic inter-
mediate and they demonstrate that it can be maintained in a
nonaggregated and foldable state. This new information sug-
gests that the development of drug cocktails that contain ubiq-
uitination blockers and chemical chaperones could increase
the cell surface expression of CFTR F508 and provide a
treatment for CF.
Figure 7. Localization of GFP–CFTR F508 in
HEK293 cells. Cells grown on glass coverslips
were transiently transfected with GFP–CFTR or
GFP–CFTR F508 with or without UbcH5a
C85A and cultured for 24 h at 37 C. Where
indicated 25  g/ml cyclohexamide and/or
brefeldin A (10  M) was added to culture
media. After 4 h of culture at 26 C these cells
were fixed and the coverslips were mounted
on glass slides. Images were collected and
processed as described in the Materials and
methods section.CFTR BIOGENESIS • YOUNGER ET AL. 1083
The nature of the folding defect that arrests the progres-
sion of CFTR F508 through its folding cascade and what
causes it to be selected for proteasomal degradation is not en-
tirely clear. One school of thought is that CFTR F508 is
highly prone to misfolding and aggregation and is therefore se-
lected for ERAD. Such a notion is supported by the observation
that inhibition of the proteasome blocks CFTR F508 degrada-
tion and drives the accumulation of ubiquitinated forms of
CFTR F508 in Triton X-100–insoluble aggregates (Ward
and Kopito, 1998). However, because the inactivation of the
Hsc70–CHIP E3 ligase leads to the accumulation of a soluble
ER localized CFTR F508 biogenic intermediate, the data we
present support a different view. It appears that inhibition of
the proteasome leads polyubiquitinated CFTR F508 to aggre-
gate because it can be extracted from the ER membrane by the
p97–UFD1–NPL4 complex (Ye et al., 2003), and because it
cannot be degraded, polyubiquitinated CFTR F508 accumu-
lates in aggresomes (Ward and Kopito, 1998). On the other
hand, the nonubiquitinated CFTR F508 that accumulates in
response to inhibition of the Hsc70–CHIP E3 does not aggre-
gate because it is inserted into the ER membrane and is bound
by cytosolic Hsc70. Thus, while CFTR F508 has a folding de-
fect that prevents it from passing quality control and escaping
the ER, it does not appear to be overly aggregation prone and
cellular chaperones can maintain it in a foldable state.
Because the cellular activity of CHIP and UbcH5a influ-
ence the partitioning of CFTR biogenic intermediates between
folding and degradation pathways, we were interested in inves-
tigating whether inhibition of the Hsc70–CHIP E3 would influ-
ence the processing efficiency of CFTR and CFTR F508. In
pulse-chase experiments UbcH5a C85A overexpression in-
creased the half-life of the B form of CFTR and CFTR F508
from two- to threefold. Therefore, UbcH5a C85A overex-
pression increased the steady-state levels of CFTR and
CFTR F508 severalfold. However, the processing efficiency
of CFTR from its B form to its C form remained at around 25%
whether or not the Hscp70–CHIP E3 complex was active.
Thus, while the elevation of cellular Hsc70–CHIP E3 activity
can divert the B form of CFTR away from its folding pathway,
the ability of full-length CFTR to stay on pathway and collapse
to the native state appears to be limited by its intrinsic folding
pathway and/or additional quality control factors.
We conclude that the E2 UbcH5a is a cytosolic factor that
functions with Hsc70 and CHIP to mediate CFTR ubiquitina-
tion. This conclusion is supported by three lines of experimental
evidence. First, purified CHIP and UbcH5a cooperated to facili-
tate the polyubiquitination of CFTR. Second, when CHIP and
UbcH5a were coexpressed together they appeared to act syner-
gistically to reduce the steady-state levels of CFTR F508.
Third, the coexpression of UbcH5a C85A with CHIP, blocked
CHIPs ability to degrade CFTR and converted it into a protein
that behaved like the CHIP U box mutant P269A.
UbcH5a is a member of a family of conserved E2 pro-
teins that include UbcH5b and UbcH5c that are nearly 90%
identical to each other (Scheffner et al., 1994; Jensen et al.,
1995b). In addition to UbcH5a, purified CHIP can interact with
UbcH5b and UbcH5c, and mRNAs for each of these E2 pro-
teins is present in all tissues tested (Jiang et al., 2001; Jensen et
al., 1995b). Thus, we propose that CHIP functions with an
UbcH5 E2 family member to ubiquitinate CFTR and other
Hsc70 substrates, but we are not able to state whether it prefers
one family member to the other. At this point, it is interesting
to note that UbcH5 proteins are related to the yeast Ubc4/5 pro-
teins that function to target misfolded proteins for degradation
and protect cells from protein denaturing physiological stress
(Seufert and Jentsch, 1990). In fact, one member of the Ubc4/5
family, Ubc1, has been shown to function on the ER surface to
ubiquitinate ERAD substrates (Bays et al., 2001). Thus, it is
logical that UbcH5 is a component of an E3 complex, which
contains molecular chaperones, that serves to prevent the accu-
mulation of toxic protein aggregates.
A potential caveat to the interpretation that Hsc70 and
CHIP interact with a UbcH5 family member to select CFTR for
degradation is that the overexpression of UbcH5a C85A may
nonspecifically inhibit the action of other cytosolic quality con-
trol factors that function on the ER surface to mediate ERAD.
Though possible, data from the control studies with the ERAD
substrates TCR  and ApoB48, whose degradation relies on
cytsolic E2s, demonstrate that their degradation was not de-
layed by overexpression of UbcH5a C85A. Thus, it appears
that the reduced rates of CFTR degradation caused by UbcH5a
C85A overexpression are due to specific inactivation of the
Hsc70–CHIP–UbcH5 E3 complex.
The E2s Ubc6 and Ubc7 function with E3s such as gp78
and Doa10 on the cytoplasmic face of the ER to ubiquitinate a
variety of substrates (Cyr et al., 2002). Hence, it is plausible
that E2–E3 complexes that contain Ubc6 and/or Ubc7 function
to select CFTR and CFTR F508 for degradation. Sommer
and colleagues have explored this concept and found that
overexpression of Ubc6, but not Ubc7, modulates the rate of
CFTR F508 degradation (Lenk et al., 2002). When we com-
pared the effect that dominant negative forms of Ubc6, Ubc7,
and UbcH5a had on CFTR and CFTR F508 expression,
UbcH5a C85A and Ubc6 C91S drove the accumulation of the
B form of CFTR, whereas Ubc7 had no apparent effect. The in-
fluence that UbcH5a C85A had on the accumulation of the B
form of CFTR and CFTR F508, was markedly more dramatic
than that of Ubc6 C91S, yet Ubc6 clearly plays a role in CFTR
quality control. Studies in yeast demonstrate that Ubc6 cooper-
ates with the transmembrane E3 Doa10 to degrade membrane
and cytosolic proteins (Swanson et al., 2001) and Doa10 is re-
quired for efficient CFTR turnover in yeast (Gnann et al.,
2004). Thus, the Doa10–Ubc6 E3 may function alongside the
Hsc70–CHIP–UbcH5 E3 to mediate quality control of CFTR.
The Hsc70–CHIP–UbcH5 E3 recognizes cytosolic regions of
CFTR, whereas the Doa10/Ubc6 E3 may recognize unassem-
bled transmembrane regions. This scenario would explain why
turnover of the B form of CFTR and CFTR F508 is delayed,
but not completely blocked, by the inactivation of the Hsc70–
CHIP E3 complex. A critical question pertaining to the func-
tion of CHIP as a quality control factor is related to the mecha-
nism by which it regulates Hsc70 polypeptide binding and
protein folding activity. The data presented suggest that CHIP
functions via a two-step mechanism to determine the fate ofJCB • VOLUME 167 • NUMBER 6 • 2004 1084
Hsc70 clients such as CFTR. The first step involves the binding
of CHIP to the COOH-terminal EEVD motif in the lid domain
of Hsc70 (Ballinger et al., 1999; Scheufler et al., 2000). This
event alters the Hsc70 polypeptide binding and release cycle to
arrest CFTR folding and may involve the transient stabilization
of Hsc70–CFTR complexes. This putative event would give
the U box on CHIP the time required to attract UbcH5 to
Hsc70–CFTR complexes and facilitate CFTR ubiquitination.
Interestingly, the ability of CHIP to ubiquitinate Hsc70
clients can be modified by other cochaperones. Data presented
herein demonstrate that Hdj-2 cooperates with Hsc70 and
CHIP to mediate CFTR ubiquitination. However, the cochaper-
one HspBP1, which is a member of a family of nucleotide ex-
change factors that promote substrate release from Hsc70,
blocks the ability of CHIP to ubiquitinate CFTR (Alberti et al.,
2004). Thus, the fate of proteins that are bound to Hsc70 is reg-
ulated by its interactions with multiple cochaperones. To un-
derstand this process, the temporal relationship and driving
force for interactions between Hsc70 and its folding or degra-
datory cochaperones needs to be determined.
Materials and methods
Plasmids and antibodies
The plasmids used for cell transfection were: pCDNA3.1CFTR and
pCDNA3.1CFTR F508 (Meacham et al., 2001); pEGFPC2-CFTR and
pEGFPC2-CFTR F508 (Moyer et al., 1998); pCDM8 2B4 TCR  (Boni-
facino et al., 1989); pCDNA-ApoB48 (H. Ginsberg, Columbia Presbyte-
rian Medical Center, New York, NY); pCAGGS His6UBCH5A C85A and
pCAGGS His6UBCH5A (Jiang et al., 2001); pCMVPLDmyc-UBC6
and pCMVPLDmyc-UBC6 C91S (Lenk et al., 2002); pCDNA myc-UBC7 and
pCDNA myc-UBC7 C89S (Tiwari and Weissman, 2001); pCDNA3.1CHIP,
pCDNA3.1CHIP K30A, and pCDNA3.1CHIP P269A (Jiang et al., 2001;
Meacham et al., 2001). pGEXCFTR 371–855 was termed pGSTNBD1-R
(Naren et al., 1999).
The following plasmids were used for overexpression of the indi-
cated proteins in E. coli; pET9d Hdj2 and pET11a Hsc70 (Meacham et
al., 1999). Plasmids prepared for this study were pET11a His6UbcH5a,
pET11a-His6UbcH5a C85A, pET11d His6Ubc7, pET11a His6Ubc6 1–243,
pET30His6CHIP, pET30His6CHIPK30A, pET30His6CHIPH260A, and pET30
His6CHIPP269A. E1 was purchased from Calbiochem.
The antibodies used for Western blots and/or immunoprecipita-
tions were  CFTR clone MM13-4 from Upstate Biotechnology and  CFTR
R-domain antibody from R&D Systems.  TCR was from BD Biosciences
and  Hsc70 was from Stressgen Biotechnologies.
Protein purification
The proteins used in in vitro ubiquitination assays were purified after over-
expression in E. coli. Hsc70 was purified by a combination of ATP–aga-
rose and anion exchange chromatography (Cyr et al., 1992). Hdj-2 was
purified by anion exchange and hydroxyapatite chromatography (Mea-
cham et al., 1999). His6-tagged proteins were purified by metal chelate
chromatography (Lu and Cyr, 1998).
GstNBD1-R was expressed in E. coli strain BL21 (DE3) and cells
from a 600-ml culture were harvested after a 16-h induction at 30 C with
0.2 mM IPTG. Cell pellets were resuspended and incubated for 30 min on
ice in 10 mM Tris-HCl, pH 8.0, 1 mM EDTA, 150 mM NaCl, 1 mM phe-
nylmethyl sulfonyl fluoride, 1 mM DTT, and lysozyme 0.1  g/ml. The ex-
tract was supplemented with 1% sarkosyl and sonicated. Gst–NBD1–R
was then purified with glutathione–agarose beads and had a final con-
centration near 2 mg/ml.
Reconstitution of CFTR ubiquitination
The experimental conditions for the reconstitution of gst–NBD1–R ubiqui-
tination were described previously (Koegl et al., 1999). Ubiquitination as-
says were performed in a reaction buffer composed of 20 mM Hepes, pH
7.4, 50 mM NaCl, 5 mM MgCl2, 2.5 mM ATP, 2 mM DTT, 10  M bo-
vine ubiquitin, 0.1  M rabbit E1 and 1  M gst–NBD1–R. The indicated E2
protein was added at 4  M and the other factors were included at the
concentration indicated in Fig. 1. Incubations were performed at 37 C for
the indicated time and terminated by the addition of 20  l of SDS sample
buffer to 25  l reaction cocktails. Proteins were resolved on 7% SDS-
PAGE gels and then transferred to nitrocellulose membranes that were
decorated with  R domain antibody and developed.
Assays for CFTR biogenesis
HEK293 and Cos-7 cells were maintained in DMEM supplemented with
10% fetal bovine serum and a mixture of 1% penicillin and streptomycin
at 37 C and transfected with CFTR and CFTR F508 expression plasmids.
Steady-state levels of CFTR and CFTR F508 levels were determined by
Western blot and CFTR processing efficiency was measured by pulse
chase analysis (Meacham et al., 2001). Details of the protocols for direct
immunoprecipitations or coimmunoprecipitations were as described previ-
ously (Meacham et al., 2001). To verify the identity of CFTR isolated from
chaperone complexes CFTR was reimmunoprecipitated from coimmuno-
precipitates with  -CFTR (Meacham et al., 1999). Treatment of cell ex-
tracts with endoglycosidase H was conducted as described previously
(Meacham et al., 1999).
Fluorescence microscopy
HEK293 cells were cultured on glass coverslips and transfected transiently
with 1 g pEGFPC2–CFTR or pEGFPC2–CFTR F508 either alone or in
combination with 3  g pCAGGS His6UBCH5A C85A. 24 h later, cells
were washed twice for 5 min with 2 mls of PBS and fixed with 4% parafor-
maldehyde at room temperature. As indicated, cells were grown for 24 h
after transfection and then treated with 25  g/ml cyclohexamide and in-
cubated for an additional 4 h at 26 C. Coverslips were mounted on glass
slides with the preservative Fluoromount-G. Images were collected using a
Nikon E600 microscope and a Princeton Instruments CCD camera. Im-
ages were processed with Metamorph (Universal Imaging Corp.) and
Adobe Photoshop software.
Online supplemental material
Data presented in Fig. S1 demonstrate that the joint presence of Hsc70,
Hdj-2, and CHIP stimulates dramatically the rate at which UbcH5a conju-
gates gst–NBD1–R with ubiquitin. When Hsc70 or Hdj-2 were omitted
from reactions mono-, di-, and triubiquitination of gst–NBD1–R was ob-
served, but this reaction was slow and inefficient. Thus, Hsc70, Hdj-2, and
CHIP act jointly to stimulate the ubiquitination activity of UbcH5a and
therefore exhibit an activity that fits the definition of a multisubunit E3 ubiq-
uitin ligase. Fig. S1 is available at http://www.jcb.org/cgi/content/full/
jcb.200410065/DC1.
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